Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1310

Sort by

Sort Order Select

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Approaching Venous Thromboembolism Disease (DVT) from Another Perspective: Better Management in a Multidisciplinary DVT Unit Improves Clinical Outcomes and Post Thrombotic Syndrome. One-Year Experience in Our Hospital

Milagros Suito, MD, Maria Cerdá, MD, Olga Benítez, MD, Alba Cabirta, MD, Francesc Bosch, MD PhD, Amparo Santamaria, MD PhD

Blood (2019) 134 (Supplement_1): 2431.

https://doi.org/10.1182/blood-2019-131327

Published: 2019

Journal Articles

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Vishal K Gupta, MD, Romy Carmen Lawrence, MD BS, Sarah L. Khan, Rachel Strykowski, MD, Brittany Scarpato, MD, Robyn T. Cohen, MD MPH, John Mark Sloan, MD, Elizabeth S Klings, MD

Blood (2019) 134 (Supplement_1): 2272.

https://doi.org/10.1182/blood-2019-122113

Published: 2019

Journal Articles

Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

Shayi Jiang, MD, Eric S. Sandler, MD, Hui Jiang, PhD

Blood (2019) 134 (Supplement_1): 2368.

https://doi.org/10.1182/blood-2019-124827

Published: 2019

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Impact of Pre-Engraftment Cytomegalovirus Viraemia in Allogeneic Haematopoetic Stem Cell Transplant Recipients

Joanne L C Tan, MBBS, Shio Yen Tio, MBBS, FRACP, Michelle K Yong, MBBS, FRACP, MPH, PhD, David Ritchie, MD PhD

Blood (2019) 134 (Supplement_1): 5656.

https://doi.org/10.1182/blood-2019-122368

Published: 2019

Journal Articles

Real World Treatment Patterns and Toxicity Among Elderly Patients with Multiple Myeloma

Jesus D Gonzalez-Lugo, MD, Ana Acuna-Villaorduna, MD, Joshua Heisler, MD, Niyati Goradia, MBBS, Daniel Cole, MD, Mateo Mejia Saldarriaga, MD, Aditi Shastri, MD, Gurbakhash Kaur, MD, Ira Braunschweig, MD, Noah Kornblum, MD, Amit Verma, MBBS, Murali Janakiram, MD MS, Ioannis Mantzaris, MD MS

Blood (2019) 134 (Supplement_1): 5571.

https://doi.org/10.1182/blood-2019-131114

Published: 2019

Journal Articles

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Tim J Peterson, PharmD, Neha Korde, MD, Hani Hassoun, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, Urvi A Shah, MD, Eric L Smith, MD PhD, Sydney X Lu, MD PhD, Heather J Landau, MD, Gunjan L. Shah, MD, Michael Scordo, MD, Oscar B Lahoud, MD, Sergio A Giralt, MD, Ola Landgren, MD PhD

Blood (2019) 134 (Supplement_1): 5554.

https://doi.org/10.1182/blood-2019-124376

Published: 2019

Journal Articles

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Sayeef Mirza, MDMPH, Ankita Tandon, DO, Dakota Jenneman, MD, Shu Cao, MD, Ambuj Kumar, MD MPH, Michelle R. Kidd, PharmD, Farhad Khimani, MD, Asmita Mishra, MD, Hien D. Liu, MD, Taiga Nishihori, MD, Lia Perez, MD, Nelli Bejanyan, MD, Joseph Pidala, MD, Michael Nieder, MD, Hany Elmariah, MD MS

Blood (2019) 134 (Supplement_1): 5673.

https://doi.org/10.1182/blood-2019-127370

Published: 2019

Journal Articles

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Xavier Leleu, MD PhD, Jo Caers, MD PhD, Barbara Gamberi, MD, Maaike Söhne, MD, Sonja Heibl, MD, Florence Suzan, MD, Abeera Mohammad, Sally Wetten, Evangelos Terpos, MD

Blood (2019) 134 (Supplement_1): 5578.

https://doi.org/10.1182/blood-2019-122938

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4297.

https://doi.org/10.1182/blood-2019-130912

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Nicole Kucine, MD, Shayla Bergmann, MD, Spencer Krichevsky, BS, Devin Jones, MS, Michael E. Rytting, MD, Linda Resar, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4194.

https://doi.org/10.1182/blood-2019-124023

Published: 2019

Journal Articles

Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Guadalupe Belen Antelo, MD, Giacomo Coltro, MD, Abhishek A Mangaonkar, MBBS, Terra Lasho, PhD, Christy Finke, BS, Ryan M. Carr, MD PhD, Naseema Gangat, MBBS, Moritz Binder, MDMPH, Aref Al-Kali, MD, Michelle A Elliott, MD, Matthew T Howard, MD, Rebecca L. King, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 4182.

https://doi.org/10.1182/blood-2019-126199

Published: 2019

Journal Articles

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive, MD, Matthieu Groh, MD, Guillaume Lefèvre, MD PhD, Chafika Morati Hafsaoui, MD, Magda Alexis, MD, Mathilde Hunault, MD PhD, Julien Seneschal, MD PhD, Hilaire Charlanne, MD, Claude Preudhomme, PharmD, PhD, Bernard Bonnotte, MD PhD, Jean Emmanuel Kahn, PhDMD

Blood (2019) 134 (Supplement_1): 2322.

https://doi.org/10.1182/blood-2019-131687

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

AL patients don’t dare go without dara

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Approaching Venous Thromboembolism Disease (DVT) from Another Perspective: Better Management in a Multidisciplinary DVT Unit Improves Clinical Outcomes and Post Thrombotic Syndrome. One-Year Experience in Our Hospital

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Impact of Pre-Engraftment Cytomegalovirus Viraemia in Allogeneic Haematopoetic Stem Cell Transplant Recipients

Real World Treatment Patterns and Toxicity Among Elderly Patients with Multiple Myeloma

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only